the fda matters November 07, 2017 Get link Facebook Twitter Pinterest Email Other Apps the fda matters “The company has received a warning letter issued by the United States Food and Drug Administration (USFDA) on November 6, 2017 for our formulation manufacturing facilities at Goa and Indore (Pithampur Unit II)”, Lupin said in a filing to BSE. Comments
Comments